Abstract
Raloxifene is an anti-resorptive agent used in postmenopausal osteoporosis. This is the first report of the occurrence of clinically significant hypocalcemia following raloxifene treatment in a patient with occult vitamin D deficiency. Since vitamin D deficiency is widely prevalent in the community, screening for vitamin D deficiency and its correction is advisable before the initiation of anti-resorptive therapy.
MeSH terms
-
Aged, 80 and over
-
Bone Density Conservation Agents / adverse effects*
-
Bone Density Conservation Agents / therapeutic use
-
Female
-
Humans
-
Hypocalcemia / chemically induced*
-
Mass Screening / methods
-
Osteoporosis, Postmenopausal / drug therapy
-
Raloxifene Hydrochloride / adverse effects*
-
Raloxifene Hydrochloride / therapeutic use
-
Vitamin D Deficiency / complications
-
Vitamin D Deficiency / diagnosis
Substances
-
Bone Density Conservation Agents
-
Raloxifene Hydrochloride